Valuation : KemPharm, Inc.

Market Cap 745M 641M 603M 551M 1.03B 70.31B 1.03B 7.12B 2.76B 36.07B 2.8B 2.74B 116B P/E 2026 *
11.2x
P/E 2027 * 14x
Enterprise Value 745M 641M 603M 551M 1.03B 70.31B 1.03B 7.12B 2.76B 36.07B 2.8B 2.74B 116B EV / Sales 2026 *
4.86x
EV / Sales 2027 * 4.19x
Free-Float
96.19%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 10/10/2023
Director of Finance/CFO 54 09/03/2026
Compliance Officer 55 25/06/2024
Director TitleAgeSince
Chairman 67 08/05/2023
Director/Board Member 59 25/04/2023
Director/Board Member 56 25/04/2023
Change 5-day change 1-year change 3-year change Capi.($)
-4.32%+29.70% - - 745M
-1.26%+1.42%+79.01%+39.95% 376B
-1.45%-3.14%+25.21%-19.54% 69.66B
-0.33%+4.52%+50.02%+169.23% 12.57B
-1.09%-8.19%-8.66%-9.78% 8.18B
+0.23%-1.59%-17.52%+5.48% 4.98B
0.00%-1.57%-31.08%+21.23% 4.47B
-0.35%-4.84%-34.66%-1.37% 3.08B
+0.27%+0.55%-3.21%+38.44% 2.56B
-0.50%-8.96%-26.58%-17.91% 2.01B
Average -0.88%-1.79%+3.61%+25.08% 53.71B
Weighted average by Cap. -1.21%-1.09%+65.40%+32.85%

Financials

2026 *2027 *
Net sales 153M 132M 124M 113M 212M 14.47B 213M 1.47B 569M 7.43B 576M 563M 23.92B 178M 153M 144M 131M 246M 16.78B 247M 1.7B 660M 8.61B 667M 653M 27.73B
Net income 68.14M 58.64M 55.17M 50.4M 94.27M 6.43B 94.53M 652M 253M 3.3B 256M 250M 10.63B 55.27M 47.56M 44.75M 40.88M 76.47M 5.22B 76.68M 529M 205M 2.68B 208M 203M 8.63B
Net Debt - -
Logo KemPharm, Inc.
Zevra Therapeutics, Inc. is a commercial-stage rare disease company with a late-stage pipeline committed to bringing therapeutics to people living with rare diseases. Its commercial products and active development assets are MIPLYFFA, Arimoclomol, OLPRUVA, and Celiprolol. Its lead product, Niemann-Pick disease type C (NPC), is a rare, progressive neurodegenerative disorder. NPC is an ultra-rare and progressive neurodegenerative disease characterized by an inability of the body to transport cholesterol and lipids inside of cells. OLPRUVA (sodium phenylbutyrate) for oral suspension is approved in the United States as adjunctive therapy to standard of care, which includes dietary management, for the chronic management of UCDs involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase, or argininosuccinic acid synthetase. Celiprolol is a selective adrenoceptor modulator (SAM). Celiprolol is approved in certain EU states for the treatment of hypertension and angina.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-